The LNT model is the best we can do - today

被引:28
|
作者
Preston, RJ [1 ]
机构
[1] US EPA, Div Environm Carcinogenesis, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA
关键词
D O I
10.1088/0952-4746/23/3/303
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
The form of the dose-response curve for radiation-induced cancers, particularly at low doses, is the subject of an ongoing and spirited debate. The present review describes the current database and basis for establishing a low dose, linear no threshold (LNT) model. The requirement for a dose-response model to be used for risk assessment purposes is that it fits the great majority of data derived from epidemiological and experimental tumour studies. Such is the case for the LNT model as opposed to other nonlinear models. This view is supported by data developed for radiation-induced mutations and chromosome aberrations. Potential modifiers of low dose cellular responses to radiation (such as adaptive response, bystander effects and genomic instability) have not been shown to be associated with tumour development. Such modifiers tend to influence the slope of the dose-response curve for cellular responses at low doses and not the shape-thereby resulting in a quantitative modification rather than a qualitative one. Additional data pertinent to addressing the shape of the tumour dose-response relationship at low doses are needed.
引用
收藏
页码:263 / 268
页数:6
相关论文
共 50 条
  • [21] Enhancing neonatal survival: what can we do today?
    Daga, S.
    Daga, A.
    Mhatre, S.
    Ghane, V.
    JOURNAL OF PERINATOLOGY, 2016, 36 (08) : 681 - 684
  • [22] How Do RNs Today Best Stay Informed? Do We Need "Knowledge Management"?
    Dreher, H. Michael
    HOLISTIC NURSING PRACTICE, 2009, 23 (05) : 263 - 266
  • [23] Sometimes Consensus and Expert Opinion Is the Best We Can Do
    Schulick, Richard D.
    JAMA SURGERY, 2014, 149 (01) : 25 - 25
  • [24] Genetic neuromuscular disorders: what is the best that we can do?
    Laing, Nigel G.
    Ong, Royston W.
    Ravenscroft, Gianina
    NEUROMUSCULAR DISORDERS, 2021, 31 (10) : 1081 - 1089
  • [25] Preventing spinal cord injuries: Is this the best we can do?
    Pless, IB
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 162 (06) : 792 - 793
  • [26] The best pharmaceuticals for children-what can we do?
    Li, Hao
    Shi, Fang-Hong
    Huang, Shi-Ying
    Zhang, Shun-Guo
    Chen, Hui-Wen
    TRANSLATIONAL PEDIATRICS, 2020, 9 (02) : 86 - 92
  • [27] Neuromuscular disorders genetics: what is the best that we can do?
    Laing, N.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S245 - S245
  • [28] Controlling cancer pain: Is morphine the best we can do?
    Dietis, N.
    Rowbotham, D. J.
    Lambert, D. G.
    TRENDS IN ANAESTHESIA AND CRITICAL CARE, 2011, 1 (5-6) : 227 - 229
  • [29] Are We the Best We Can Be?
    Killinger, James S.
    Greenwald, Bruce M.
    PEDIATRIC CRITICAL CARE MEDICINE, 2018, 19 (06) : 592 - 593
  • [30] Can costs of hemophilia products be curtailed? Not as we do business today!
    Aledort, LM
    THROMBOSIS AND HAEMOSTASIS, 2002, 88 (04) : 541 - 541